A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney
A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney
To estimate the difference in efficacy and safety of bevacizumab and RAD001 compared to bevacizumab and interferon alfa-2a for first-line treatment of patients with metastatic carcinoma of the kidney.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Duarte, California 91010-3000, United States
Los Angeles, California 90053, United States
Los Angeles, California 90095, United States
Bethlehem, Pennsylvania, United States
Montellier Cedex 5, 34298, France
Shatin, New Territories, Hong Kong, Hong Kong
Balcova / Izmir, 35340, Turkey (Türkiye)
Mecidiyekoy/Istanbul, 34394, Turkey (Türkiye)